Clinicopathologic Features and Treatment Characteristics of Congenital Corneal Opacity Infants and Children Aged 3 Years or Less: A Retrospective Single Institution Analysis
Sign Up to like & getrecommendations! Published in 2019 at "Medical Principles and Practice"
DOI: 10.1159/000501763
Abstract: Objective: In this retrospective single institution study, we investigated the clinicopathologic features and treatment characteristics of 90 patients with congenital corneal opacities (CCO) (117 eyes) who were 3 years and younger and treated at our… read more here.
Keywords: treatment characteristics; features treatment; treatment; retrospective single ... See more keywords
Comparison of treatment characteristics between patients diagnosed with immune thrombocytopenia (ITP) and treated with thrombopoietin receptor agonists (TPO-RA).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e18314
Abstract: e18314Background: There is limited real-world information on the utilization of TPO-RAs, eltrombopag (ELT) and romiplostim (ROM), for the treatment of ITP. Methods: The study employed a retrospecti... read more here.
Keywords: treatment characteristics; comparison treatment; characteristics patients; treatment ... See more keywords
Changes in patient (pt), tumor, and treatment characteristics over time in 1st line (1L) trastuzumab (H) plus taxane (T; paclitaxel/docetaxel) arms in HER2-positive metastatic breast cancer (MBC) trials.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e13024
Abstract: e13024Background: A retrospective analysis showed improved progression-free survival and consistent underestimation of H+T efficacy assumptions in 1L HER2+ MBC trials over time (ISCB 2016). We evaluated changes in baseline/treatment characteristics and safety profile of H+T… read more here.
Keywords: treatment characteristics; mbc trials; time; tumor ... See more keywords
Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.00515
Abstract: Immunotherapies in tumors have attracted increasing attention. They play an important role in precision medicine. Many immune-checkpoint inhibitors (ICIs) have obtained FDA approval and show good performance in the clinic. Hyperprogressive disease (HPD) after ICIs… read more here.
Keywords: immune checkpoint; treatment characteristics; inhibitor treatment; hyperprogression immune ... See more keywords